NCT02765854View on ClinicalTrials.gov

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

May 23, 2023

Study Completion Date

May 23, 2023

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Dexamethasone

Given PO

DRUG

Ixazomib

Given PO

DRUG

Lenalidomide

Given PO

Trial Locations (4)

30303

Grady Memorial Hospital, Atlanta

30322

Emory University/Winship Cancer Institute, Atlanta

48109

University of Michigan/Rogel Cancer Center, Ann Arbor

63110

Washington University/Siteman Cancer Center, St Louis

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

Multiple Myeloma Research Consortium

NETWORK

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER